Abstracts tagged "Clinical practice"

Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…
Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Stephanie Shoop¹, Suzanne M. Verstappen², Eileen Baildam³, Alice Chieng⁴, Joyce Davidson^5,6, Helen Foster⁷, Yiannis Ioannou⁸, Flora McErlane⁷, Lucy R Wedderburn⁹, Wendy Thomson¹⁰ and Kimme L. Hyrich¹⁰, ¹ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, ²ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁵The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, ⁶The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, ⁷Royal Victoria Hospital, Newcastle, United Kingdom, ⁸Rayne Institute, University College London, London, UK, London, United Kingdom, ⁹Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, ¹⁰arc Epidemiology Unit, Manchester, United Kingdom
Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…
Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Leticia Leon¹, Luis Rodriguez-Rodriguez¹, Alejandro Gomez-Gomez², Pilar Macarrón², Margarita Blanco², Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…
Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting
Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
Abstract Number: 1276 • 2015 ACR/ARHP Annual Meeting
Improvement in Work and Household Productivity for Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with Anti-TNFs in Routine Clinical Practice in Turkey
Sebnem Ataman¹, Mehmet Kirnap², Buminhan Seferoglu³, Zuhal Altay⁴, Aylin Rezvani⁵, Omer Kuru^6,7, Erhan Capkin⁸, Nazli Derya Bugdayci⁹, Ilhan Sezer¹⁰, Hasan Fatih CAY¹¹ and Akinci Tan¹², ¹Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Erciyes University, Kayseri, Turkey, ³Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey, ⁴ELAZIG KARAYOLU UZERI, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey, ⁵Department of Physical Medicine and Rehabilitation, Bezmialem Foundation University, İstanbul, Turkey, ⁶Kurupelit Mevkii Kurupelit 552, Ondokuz Mayis Univ.Tip Fak.Has.-Fizik Tedavi, Samsun, Turkey, ⁷Physical Medicine and Rehabilitation, Ondokuz Mayis University, Samsun, Turkey, ⁸PM&R AND RHEUMATOLOGY, Karadeniz Tecnical University, Faculty of Medicine, TRABZON, Turkey, ⁹Physical Treatment and Rehabilitation, Istanbul Physical Treatment and Rehabilitation Training and Research Hospital, Istanbul, Turkey, ¹⁰Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ¹¹Rheumatology, Physical Medicine&Rehabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ¹²Physical Med & Rehab, Hacettepe Univ, Ankara, Turkey
Background/Purpose: The impact of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) on paid work is measured on the basis of employed people missing time from…
Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Benjamin Chastek¹, Jeffrey R. Curtis², Laura K. Becker³, George J. Joseph⁴ and Chieh-I Chen⁵, ¹Optum Insight, Eden Prairie, MN, ²University of Alabama at Birmingham, Birmingham, AL, ³Optum, Eden Prairie, MN, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…
Abstract Number: 1715 • 2015 ACR/ARHP Annual Meeting
Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos², Hilde Berner Hammer³, Arthur Kavanaugh⁴ and Glenn Haugeberg^1,5,6, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Haugesund Rheumatism Hospital, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway
Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in…
Abstract Number: 1717 • 2015 ACR/ARHP Annual Meeting
Factors Associated with the Decision of the Rheumatologist to Order Sacro-Iliac Joints Magnetic Resonance Imaging (SI-MRI) or Order HLA-B27 Testing in Patients with Spondyloarthritis in Clinical Practice
Wilson Bautista-Molano^1,2, Robert Landewé³, Cesar Serna⁴, Rafael R. Valle⁵ and Désirée van der Heijde⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogotá, Colombia, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Statistics and Mathematics Department, Universidad Central, Bogotá, Colombia, Bogotá, Colombia, ⁵Rheumatology/Immunology, Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogota, Colombia, ⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Magnetic resonance imaging of sacroiliac joints (MRI-SI) and HLA-B27 testing are important tools in the diagnosis of spondyloarthritis (SpA). The aim of the study…
Abstract Number: 1977 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales^1,2, Lucía Arietti¹, Leticia Leon², Inmaculada Morado¹, Benjamín Fernández-Gutiérrez³, Luis Rodriguez-Rodriguez², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It has is been demonstrated the safety and efficacy of Methotrexate (MTX) in the treatment of Giant Cell Arteritis (GCA) in clinical trials, but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].